Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). $125.0M private placement at $56.00 per share, funding clinical development, commercialization, and general corporate needs.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $125.0M private placement at $56.00 per share, funding clinical development, commercialization, and general corporate needs
- 2,098,519 shares plus pre-funded warrants for 133,625 shares, creating potential dilution of 2,232,144 shares
- Closing expected August 7, 2026, subject to customary conditions
- 90-day company and insider lock-ups restrict additional equity sales, supporting near-term capital structure stability
- Investors receive resale registration rights, potentially increasing future trading supply once registered
Item 8.01 · Other Events
- Private placement pricing announced August 6, 2026
- Financing terms and proceeds require review of Exhibit 99.1
- Potential dilution and liquidity impact depend on securities issued and pricing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.